DaVita (NYSE:DVA) Hits New 12-Month High – Here’s Why

DaVita Inc. (NYSE:DVA)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $169.12 and last traded at $168.37, with a volume of 216981 shares trading hands. The stock had previously closed at $165.51.

Analysts Set New Price Targets

Several equities research analysts have commented on DVA shares. Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. UBS Group increased their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Stock Down 1.3 %

The company has a market capitalization of $13.59 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.94 and a beta of 0.89. The company’s fifty day moving average is $158.42 and its 200-day moving average is $148.87. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the company earned $2.85 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, analysts predict that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On DaVita

Several institutional investors have recently bought and sold shares of the stock. Transcendent Capital Group LLC purchased a new stake in DaVita in the 3rd quarter worth $25,000. Blue Trust Inc. increased its holdings in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. purchased a new stake in shares of DaVita in the second quarter worth about $43,000. Versant Capital Management Inc boosted its stake in DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after buying an additional 155 shares during the last quarter. Finally, Friedenthal Financial purchased a new position in DaVita during the 2nd quarter valued at approximately $48,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.